Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen tEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, Q2 2026
576
Period ended Jun 30, 2026
Change on a year earlier
+14.1%
505 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
9
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 576 | +14.1% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 490 | +28.6% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 457 | -0.7% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 560 | +14.8% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 505 | +5.4% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 381 | -10.1% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 460 | +2.7% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 488 | – | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 479 | – | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 424 | – | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 448 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 0 | – | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 0 | – | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 0 | – | Form 10-Q (filed 2024-05-03) ↗ |
Breakdown
What makes up tepezza (teprotumumab-trbw — thyroid eye disease) — worldwide product sales ($m)
Cite this data
StockData. (2026). Amgen TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide product sales ($M) ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_tepezza_ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.